Other News To Note
Friday, July 29, 2011
Soligenix Inc., of Princeton, N.J., expanded its North American licensing partnership with Sigma-Tau Pharmaceuticals Inc., of Rome, for the development and commercialization of orBec (oral beclomethasone dipropionate) in Europe. The amended agreement includes a $5 million up-front payment to Soligenix, along with a possible $11 million in milestones and 40 percent royalties on net sales.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.